Global Biosimilar Insulin Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Biosimilar Insulin Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product"s patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

According to our (Global Info Research) latest study, the global Biosimilar Insulin market size was valued at US$ 3038 million in 2023 and is forecast to a readjusted size of USD 7467 million by 2030 with a CAGR of 13.9% during review period.

Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent

This report is a detailed and comprehensive analysis for global Biosimilar Insulin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Distribution Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Biosimilar Insulin market size and forecasts, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (US$/Unit), 2019-2030

Global Biosimilar Insulin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (US$/Unit), 2019-2030

Global Biosimilar Insulin market size and forecasts, by Type and by Distribution Channel, in consumption value ($ Million), sales quantity (K Unit), and average selling prices (US$/Unit), 2019-2030

Global Biosimilar Insulin market shares of main players, shipments in revenue ($ Million), sales quantity (K Unit), and ASP (US$/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Biosimilar Insulin

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Biosimilar Insulin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Biosimilar Insulin market is split by Type and by Distribution Channel. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Distribution Channel in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other

Market segment by Distribution Channel
Hospital
Retail Pharmacy
Others

Major players covered
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Biosimilar Insulin product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Biosimilar Insulin, with price, sales quantity, revenue, and global market share of Biosimilar Insulin from 2019 to 2024.

Chapter 3, the Biosimilar Insulin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Biosimilar Insulin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Distribution Channel, with sales market share and growth rate by Type, by Distribution Channel, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Biosimilar Insulin market forecast, by regions, by Type, and by Distribution Channel, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Insulin.

Chapter 14 and 15, to describe Biosimilar Insulin sales channel, distributors, customers, research findings and conclusion.